BridgeBio Oncology Therapeutics, Inc. (BBOT) — Cash Flow Quality Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow Quality Index of -0.04x as of December 2024. Operating cash flow of $-87.86K is below net income of $1.95 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow to debt ratio of BridgeBio Oncology Therapeutics, Inc. to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BridgeBio Oncology Therapeutics, Inc. Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see BBOT operating cash flow.
Annual Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. (2024–2024)
Year-by-year earnings quality comparison for BridgeBio Oncology Therapeutics, Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | $-763.82K | $7.60 Million | — |